Myeloma

The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

Here’s a look back at blood cancer approvals from the summer of 2023.

As majority leader Steve Scalise announces his new cancer diagnosis and author Ibram X. Kendi reveals that he is cancer free, this is what’s happening in the oncology space this week.

Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.

The recent FDA approval of Talvey for heavily pretreated multiple myeloma results in an improved response to therapy and a manageable side effect profile.

With multiple therapies available for patients with myeloma, there are some considerations that patients should discuss with their clinicians before choosing which one is right for them, an expert said.

The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy.

The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.

Momelotinib led to symptom, spleen and anemia benefits for patients with previously treated myelofibrosis, according to updated study findings.

Supervised exercise can help to improve the immune system for patients with myeloma, recent research showed.

It is essential for patients to live a healthy lifestyle while undergoing treatment for multiple myeloma, an expert said.

CAR-T cell therapies have not always been easy to access for patients with myeloma, though that is slowly changing, an expert explained.

Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.

Cryopreserved stem cells led to a higher rate of relapse in patients with blood cancer, though there was no difference in survival, research showed.

Mixed in the boxes of appointments and cancer treatments are milestones that uplift my spirits and are unique to my healing journey.

Watch Dr. Brandon J Blue, Dr. Surbhi Sidana, Dr. Kenneth H. Shain and Mary Derome answer questions about the future of treatment during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Kenneth H. Shain, from Moffitt Cancer Center, discuss the future of myeloma treatment, including BiTE therapy, during the CURE Educated Patient Multiple Myeloma Summit.

Patients with myeloma who are being treated with Tecvayli must discuss symptoms of cytokine release syndrome with their providers as soon as they happen.

Watch Dr. Surbhi Sidana, from Stanford Medicine, discuss CAR-T cell therapy during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Brandon J Blue, Dr. Dickran Kazandjian and Dr. Marc J. Braunstein answer questions about disease management during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Marc Braunstein, from NYU Langone Hospital, discuss the role of bone marrow transplant during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Dickran Kazandjian, from Miami Health System, discuss updates in newly diagnosed disease during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Ariel Grajales-Cruz and Dr. Brandon J Blue answer questions about myeloma during the CURE Educated Patient Multiple Myeloma Summit.